Gui G P, Puddefoot J R, Vinson G P, Wells C A, Carpenter R
Department of Surgery, St. Bartholomew's Hospital, London, UK.
Surgery. 1995 Aug;118(2):245-50. doi: 10.1016/s0039-6060(05)80330-7.
Very late activation-2 (VLA-2) is an integrin receptor for laminin that consists of an alpha 2- and a beta 1-subunit. In human breast cancer, down-regulation of VLA-2 expression is related to positive nodal status. The functional significance of altered integrin expression in individual patients has never been investigated. To test the hypothesis that less adhesive primary breast cancer cells were predisposed to metastasize, variation in VLA-2 modulation of cell attachment to laminin with nodal status was studied.
Integrin expression was measured by means of immunohistochemistry on cryostat sections. Primary breast cancer cells were isolated by enzymatic disaggregation and immunomagnetic separation. Cell adhesion to laminin was evaluated in an in vitro assay, and the effect of monoclonal antibodies against the component subunits of VLA-2 was assessed.
Adhesion of primary breast cancer cells from women with positive nodes to laminin was significantly reduced compared with women with negative nodes (p < 0.001, Wilcoxon signed rank test). VLA-2 antibodies inhibited primary breast cancer cell attachment of women with negative nodes but not women with positive nodes. Strong adhesion to laminin was related to node-negative status (chi-squared, 16.33; p < 0.001) and to positive integrin expression (chi-squared, 31.54; p < 0.001).
VLA-2-mediated adhesion of primary breast cancer cells to laminin differs with nodal status. Measurement of VLA-2 expression may thus be of clinical value as a prognostic indicator in the assessment of breast cancer.
极迟活化抗原-2(VLA-2)是层粘连蛋白的整合素受体,由α2亚基和β1亚基组成。在人类乳腺癌中,VLA-2表达下调与阳性淋巴结状态相关。从未研究过个体患者中整合素表达改变的功能意义。为了验证黏附性较低的原发性乳腺癌细胞易于转移这一假说,研究了VLA-2调节细胞与层粘连蛋白黏附的情况随淋巴结状态的变化。
通过免疫组织化学在低温恒温器切片上测量整合素表达。通过酶解聚和免疫磁珠分离法分离原发性乳腺癌细胞。在体外试验中评估细胞与层粘连蛋白的黏附情况,并评估抗VLA-2组成亚基的单克隆抗体的作用。
与淋巴结阴性的女性相比,淋巴结阳性女性的原发性乳腺癌细胞与层粘连蛋白的黏附显著降低(p<0.001,Wilcoxon符号秩检验)。VLA-2抗体抑制淋巴结阴性女性的原发性乳腺癌细胞黏附,但不抑制淋巴结阳性女性的细胞黏附。与层粘连蛋白的强黏附与淋巴结阴性状态(卡方检验,16.33;p<0.001)和整合素阳性表达(卡方检验,31.54;p<0.001)相关。
原发性乳腺癌细胞通过VLA-2介导与层粘连蛋白的黏附因淋巴结状态而异。因此,测量VLA-2表达作为评估乳腺癌的预后指标可能具有临床价值。